Royalty Pharma (NASDAQ:RPRX) EVP Sells $821,800.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of Royalty Pharma stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total transaction of $821,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Marshall Urist also recently made the following trade(s):

• On Friday, January 23rd, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.26, for a total value of $805,200.00.
• On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.52, for a total value of $790,400.00.
• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $40.78, for a total value of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Trading Up 1.6%

Shares of NASDAQ RPRX traded up $0.68 during midday trading on Monday, hitting $42.36. The stock had a trading volume of 3,864,065 shares, compared to its average volume of 3,852,869. The firm has a market cap of $24.45 billion, a P/E ratio of 32.09, a price-to-earnings-growth ratio of 1.59 and a beta of 0.42. Royalty Pharma PLC has a fifty-two week low of $29.66 and a fifty-two week high of $42.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The company’s 50-day simple moving average is $39.54 and its 200 day simple moving average is $37.74.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. Research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, February 20th. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 dividend on an annualized basis and a yield of 2.2%. Royalty Pharma’s payout ratio is 66.67%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on RPRX shares. Citigroup increased their price target on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Leerink Partners set a $45.00 target price on Royalty Pharma in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Royalty Pharma in a research note on Thursday, January 22nd. UBS Group raised shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective on the stock in a research note on Friday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.50.

Institutional Investors Weigh In On Royalty Pharma

Several large investors have recently made changes to their positions in RPRX. Royal Bank of Canada boosted its stake in Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock worth $6,342,000 after purchasing an additional 160,191 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Royalty Pharma by 20.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after purchasing an additional 13,489 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Royalty Pharma during the first quarter worth about $264,000. Intech Investment Management LLC grew its holdings in shares of Royalty Pharma by 41.0% during the first quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 13,951 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in Royalty Pharma by 113.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,428 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 760 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.